Simply find the best possible online shopping Microbot deals
Shop Microbot products and compare prices and listings on popular online marketplaces.
The presentation will be webcast live on April 15 at 10:15 a.m. ET. Continued Engagement with Healthcare Institutions Reflects Rising Momentum
HINGHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will highlight recent commercial achievements leading to the recent Full Market Release (FMR) of the LIBERTY System at the 25th Annual Needham Virtual Healthcare Conference, being held April 13-16th. Harel Gadot, CEO, President & Chairman of Microbot Medical, will be presenting live at 10:15 a.m. ET on Wednesday, April 15, 2026. Mr. Gadot, along with other of Microbot’s senior executives, will provide an overview of the Company and its strategic positioning, growth opportunities, and ability to address markets with multiple unmet needs, including physician radiation risks, physical strain and staffing issues.
The presentation will be webcast live and may be accessed via the ‘Investors’ section on Microbot Medical’s website at https://ir.microbotmedical.com/. Additionally, the Microbot Medical team will meet with healthcare-focused institutional investors through a series of pre-scheduled one-on-one meetings. Interested parties should reach out to their Needham sales representatives or contact [email protected] to schedule a one-on-one meeting.
LIBERTY is the only…
Microbot Medical (MBOT) has entered into definitive agreements for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered short-term series H preferred investment options. The short-term series H preferred investment options to purchase up to 7,577,100 shares of common stock have an exercise price of $2.10 per share and are immediately exercisable following issuance for a period of two years thereafter. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about January 9, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. The gross proceeds to the Company from the offerings are expected to be approximately $8.6 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offerings for the continued development, commercialization and regulatory activities for the Company’s LIBERTY Robotic System, expansion and…
Microbot Medical MBOT recently announced the successful completion of the limited market release of its LIBERTY Endovascular Robotic System and the planned transition to full market release in the United States. The system has already been utilized across multiple healthcare networks, including renowned institutions such as Emory Healthcare and Tampa General Hospital.
To support this expansion, Microbot Medical is doubling its sales territories and strengthening its commercial team, with ambitions to cover 12 territories across the United States by year-end. The company officially launched the full market release of the LIBERTY system at the Society of Interventional Radiology Annual Scientific Meeting 2026, signaling a broader commercial push.
Per management, the company met its objectives during the limited rollout of the LIBERTY System, including its adoption by leading hospitals for a range of peripheral procedures, providing strong momentum for its full commercial launch at the SIR conference. The strong enthusiasm from existing customers has been noted, as hospitals not only begin using LIBERTY across multiple procedures but also expand its use to additional sites within their networks. The diversity of procedures performed underscores the system’s versatility, while its user-friendly design is driving high customer satisfaction. The rapid adoption seen during the…